Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase…
An institutional-grade, numbers-driven thesis on CING — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates Cingulate Inc. (CING) 60/100 with a 12-month base-case forecast of $10.00 — +85.9% versus the current price of $5.38. Cingulate Inc. trades at $5.38 in the Healthcare sector, with a market capitalisation of $30.2M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for CING is $10.00, implying +85.9% versus the current price. The model's 12-month scenario range runs from $8.68 (bear) to $9.67 (bull), with a base case of $9.00.
On the fundamentals, Cingulate shows a P/E of -1.1, trailing revenue of $0, revenue growth of +0.0% YoY. This page also tracks CING's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
CING currently carries a TradersQuant composite score of 60/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $10.00 implies +85.9% from $5.38. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for CING is $10.00, about +85.9% versus the latest price of $5.38. Consensus is based on 6 analysts.
TradersQuant's 12-month model forecast for CING is a base case of $9.00, ranging from $8.68 (bear) to $9.67 (bull), an expected return of +67.4%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for CING over the next 12 months is $9.00 in the base case (bear $8.68, bull $9.67), versus today's price of $5.38. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for CING — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates CING's fair value at $10.00, implying +85.9% of expected upside versus the current price.
Cingulate does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
